{
    "clinical_study": {
        "@rank": "159641", 
        "brief_summary": {
            "textblock": "It is estimated that in the United States there are approximately 8 million individuals with\n      moderate to severe chronic kidney disease (CKD), not on dialysis. Volume expansion plays an\n      important role in the pathogenesis of hypertension in patients with CKD.  For this pilot\n      study, the investigators hypothesize that administration of chlorthalidone among patients\n      with moderate to severe CKD will improve BP."
        }, 
        "brief_title": "A Pilot Study of Chlorthalidone Among Patients With Poorly Controlled Hypertension and CKD", 
        "condition": [
            "Chronic Kidney Disease", 
            "Poorly-Controlled Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age greater than 18 years.\n\n          -  eGFR \u2264 45 ml/min/1.73m2 but \u226520 mL/min/1.73m2.\n\n          -  Poorly controlled blood pressure by 24-hour ambulatory BP monitoring.\n\n          -  Treated hypertension: use of at least one antihypertensive drug. One of the drugs\n             should be either an ACE inhibitor or angiotensin receptor blocker.  If these are\n             contraindicated then use of a beta-blocker is required.\n\n        Exclusion Criteria:\n\n          -  Use of thiazide or thiazide-like drugs in the previous 3 months.\n\n          -  Use of furosemide in a dose >200 mg/d.\n\n          -  Ambulatory BP of either \u2265160 systolic or \u2265100 mmHg by 24-hour ambulatory BP\n             monitoring.\n\n          -  Expected to receive renal replacement therapy within the next 3 months.\n\n          -  Vascular event such as myocardial infarction, heart failure hospitalization, or\n             stroke within 3 months prior to randomization.\n\n          -  Pregnant or breastfeeding women or women who are planning to become pregnant or those\n             not using a reliable form of contraception (oral contraceptives. condoms and\n             diaphragms will be considered reliable).\n\n          -  Known hypersensitivity to thiazide or sulfa drugs.\n\n          -  Organ transplant recipient or therapy with immunosuppressive agents. Nasal or inhaled\n             corticosteroids will be permitted."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01750294", 
            "org_study_id": "1206009002", 
            "secondary_id": "1206009002"
        }, 
        "intervention": {
            "intervention_name": "Chlorthalidone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Chlorthalidone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "hypertension", 
            "kidney disease"
        ], 
        "lastchanged_date": "December 13, 2012", 
        "location": {
            "contact": {
                "email": "pappas2@iupui.edu", 
                "last_name": "Maria Pappas", 
                "phone": "317-988-4591"
            }, 
            "facility": {
                "address": {
                    "city": "Indianapolis", 
                    "country": "United States", 
                    "state": "Indiana", 
                    "zip": "46202"
                }, 
                "name": "Richard L. Roudebush VAMC"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "email": "pappas2@iupui.edu", 
            "last_name": "Maria Pappas", 
            "phone": "3179884591"
        }, 
        "overall_official": {
            "affiliation": "Indiana University", 
            "last_name": "Rajiv Agarwal, MD FASN FAHA", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change of systolic ambulatory blood pressure from baseline to 12 weeks", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks after intervention"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01750294"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Indiana University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Indiana University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}